🇺🇸 FDA
Pipeline program

anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells

X01-CN-A1

Phase 1 mab active

Quick answer

anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells for Relapsed/refractory Lymphoma is a Phase 1 program (mab) at The First People's Hospital of Lianyungang with 1 ClinicalTrials.gov record(s).

Program details

Company
The First People's Hospital of Lianyungang
Indication
Relapsed/refractory Lymphoma
Phase
Phase 1
Modality
mab
Status
active

Clinical trials